GlaxoSmithKline Historical Balance Sheet

GSK -  USA Stock  

USD 39.84  0.73  1.80%

Trend analysis of GlaxoSmithKline PLC balance sheet accounts such as Accounts Payable of 3.6 B or Total Assets of 73.6 B provides information on GlaxoSmithKline PLC's total assets, liabilities, and equity, which is the actual value of GlaxoSmithKline PLC to its prevalent stockholders. By breaking down trends over time using GlaxoSmithKline PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down GlaxoSmithKline PLC prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC is a good buy for the upcoming year.
Please check Risk vs Return Analysis.

Search Historical Statements 

 
Refresh
Share

About GlaxoSmithKline Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

GlaxoSmithKline PLC Balance Sheet Chart

GlaxoSmithKline PLC Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how GlaxoSmithKline PLC uses and utilizes its capital. It also shows what exactly a company owns and owes.
GlaxoSmithKline PLC Property Plant and Equipment Net is increasing as compared to previous years. The last year's value of Property Plant and Equipment Net was reported at 11.01 Billion. The current Trade and Non Trade Receivables is estimated to increase to about 7.1 B, while Accounts Payable is projected to decrease to under 3.6 B.

Total Assets

Total assets refers to the total amount of GlaxoSmithKline PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in GlaxoSmithKline PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.

Current Assets

Current assets of GlaxoSmithKline PLC include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of GlaxoSmithKline PLC. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on GlaxoSmithKline PLC balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on GlaxoSmithKline PLC books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; [DeferredRev]; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from GlaxoSmithKline PLC balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into GlaxoSmithKline PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please check Risk vs Return Analysis.GlaxoSmithKline PLC Property Plant and Equipment Net is increasing as compared to previous years. The last year's value of Property Plant and Equipment Net was reported at 11.01 Billion. The current Trade and Non Trade Receivables is estimated to increase to about 7.1 B, while Accounts Payable is projected to decrease to under 3.6 B.
 2018 2019 2020 2021 (projected)
Receivables6.09 B6.89 B6.59 B5.87 B
Inventories5.48 B5.95 B6 B5.17 B

GlaxoSmithKline PLC balance sheet Correlations

0.70.970.910.740.92-0.190.780.640.750.180.90.970.49-0.470.510.970.90.890.870.930.790.910.79
0.70.680.790.770.790.20.70.530.70.490.790.680.580.040.580.70.670.630.560.680.920.660.8
0.970.680.930.780.94-0.110.830.710.790.270.930.950.55-0.550.580.960.830.920.80.90.790.910.85
0.910.790.930.931.00.110.860.60.880.540.990.940.74-0.370.750.940.770.920.720.90.920.90.94
0.740.770.780.930.90.380.770.430.840.720.90.820.83-0.110.820.80.630.810.560.790.920.810.86
0.920.790.941.00.90.070.860.620.870.51.00.950.71-0.40.730.950.790.930.740.910.910.90.94
-0.190.2-0.110.110.380.07-0.11-0.490.080.610.1-0.140.520.410.49-0.14-0.360.02-0.34-0.180.17-0.050.21
0.780.70.830.860.770.86-0.110.820.970.550.860.810.68-0.450.70.80.660.790.550.770.80.70.74
0.640.530.710.60.430.62-0.490.820.650.130.620.630.2-0.440.230.660.640.590.480.630.560.580.56
0.750.70.790.880.840.870.080.970.650.670.870.80.82-0.410.840.770.590.790.520.740.820.680.74
0.180.490.270.540.720.50.610.550.130.670.520.30.880.120.860.240.090.310.020.230.590.260.55
0.90.790.930.990.91.00.10.860.620.870.520.930.72-0.410.740.930.760.920.710.870.90.870.95
0.970.680.950.940.820.95-0.140.810.630.80.30.930.57-0.470.590.990.90.910.880.970.850.940.82
0.490.580.550.740.830.710.520.680.20.820.880.720.57-0.121.00.520.330.580.310.490.70.550.65
-0.470.04-0.55-0.37-0.11-0.40.41-0.45-0.44-0.410.12-0.41-0.47-0.12-0.17-0.47-0.33-0.51-0.42-0.4-0.11-0.29-0.29
0.510.580.580.750.820.730.490.70.230.840.860.740.591.0-0.170.540.340.60.330.510.70.560.66
0.970.70.960.940.80.95-0.140.80.660.770.240.930.990.52-0.470.540.880.950.840.980.850.950.84
0.90.670.830.770.630.79-0.360.660.640.590.090.760.90.33-0.330.340.880.680.970.90.770.840.67
0.890.630.920.920.810.930.020.790.590.790.310.920.910.58-0.510.60.950.680.640.90.790.890.84
0.870.560.80.720.560.74-0.340.550.480.520.020.710.880.31-0.420.330.840.970.640.850.670.790.61
0.930.680.90.90.790.91-0.180.770.630.740.230.870.970.49-0.40.510.980.90.90.850.860.940.77
0.790.920.790.920.920.910.170.80.560.820.590.90.850.7-0.110.70.850.770.790.670.860.820.88
0.910.660.910.90.810.9-0.050.70.580.680.260.870.940.55-0.290.560.950.840.890.790.940.820.79
0.790.80.850.940.860.940.210.740.560.740.550.950.820.65-0.290.660.840.670.840.610.770.880.79
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC balance sheet Accounts

201620172018201920202021 (projected)
Inventories5.1 B5.56 B5.48 B5.95 B6 B5.17 B
Receivables5.69 B5.69 B6.09 B6.89 B6.59 B5.87 B
Accounts Payable3.6 B3.53 B3.65 B4.14 B4.36 B3.64 B
Total Assets59.08 B56.38 B58.07 B79.69 B80.43 B73.63 B
Current Assets16.71 B15.91 B16.93 B19.49 B20.25 B20.22 B
Assets Non Current42.37 B40.47 B41.14 B60.2 B60.18 B53.41 B
Cash and Equivalents4.9 B3.83 B3.87 B4.71 B6.29 B5.43 B
Cash and Equivalents USD6.05 B5.18 B4.92 B6.19 B8.62 B7.62 B
Total Debt18.79 B17.09 B26.06 B30.51 B27.15 B25.95 B
Debt Current4.13 B2.83 B5.79 B6.92 B3.73 B3.91 B
Debt Non Current14.66 B14.26 B20.27 B23.59 B23.43 B22.04 B
Total Debt USD23.21 B23.09 B33.08 B40.14 B37.19 B36.26 B
Shareholders Equity1.12 B(68 M)3.78 B11.4 B14.59 B15.74 B
Shareholders Equity USD1.39 B(91.87 M)4.8 B15.01 B19.98 B21.56 B
Goodwill and Intangible Assets24.74 B23.3 B22.99 B41.52 B40.42 B33.83 B
Inventory5.1 B5.56 B5.48 B5.95 B6 B5.92 B
Investments1.34 B1.18 B1.64 B2.23 B3.5 B2.86 B
Investments Current75 M89 M78 M84 M79 M81.89 M
Investments Non Current1.25 B1.1 B1.56 B2.15 B3.42 B2.76 B
Total Liabilities54.12 B52.89 B54.39 B61.34 B59.62 B57.51 B
Current Liabilities19 B26.57 B22.49 B24.05 B22.15 B21.99 B
Liabilities Non Current35.12 B26.32 B31.9 B37.28 B37.48 B35.52 B
Trade and Non Trade Payables11.96 B20.97 B14.04 B14.94 B15.84 B14.93 B
Property Plant and Equipment Net10.81 B10.86 B11.06 B11.31 B11.01 B11.54 B
Trade and Non Trade Receivables6.03 B6 B6.42 B7.2 B6.95 B7.07 B
Accumulated Retained Earnings Deficit(5.39 B)(6.48 B)(2.72 B)4.53 B6.75 B7.29 B
Tax Assets4.6 B4.05 B4.12 B4.36 B4.96 B4.62 B
Tax Liabilities3.24 B2.8 B2.39 B4.63 B4.32 B3.88 B

GlaxoSmithKline PLC Investors Sentiment

The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GlaxoSmithKline PLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the GlaxoSmithKline PLC information on this page should be used as a complementary analysis to other GlaxoSmithKline PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for GlaxoSmithKline PLC Stock analysis

When running GlaxoSmithKline PLC price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of GlaxoSmithKline PLC is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GlaxoSmithKline PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.